Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)

被引：0
|
作者：
Brioli, A. [1 ,2 ]
Pezzi, A. [2 ]
Muegge, L-O [1 ]
Derudas, D. [3 ]
Petti, M. C. [4 ]
Zannetti, B. A. [2 ]
Ferrara, F. [5 ]
Rocchi, S. [2 ]
Nobile, F. [6 ]
Baraldi, A. [7 ]
Musto, P. [8 ]
Lanza, F. [9 ]
Mancuso, K. [2 ]
Canepa, L. [10 ]
Catalano, L. [5 ]
Lazzaro, A. [11 ]
Pinotti, G. [12 ]
Boccadoro, M. [13 ]
Hochhaus, A. [1 ]
Cavo, M. [2 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 2, Hamatol & Internist Onkol, Jena, Germany
[2] Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy
[3] GIMEMA, Italian Myeloma Network, Cagliari, Italy
[4] GIMEMA, Italian Myeloma Network, Rome, Italy
[5] GIMEMA, Italian Myeloma Network, Naples, Italy
[6] GIMEMA, Italian Myeloma Network, Reggio Di Calabria, Italy
[7] GIMEMA, Italian Myeloma Network, Alessandria, Italy
[8] GIMEMA, Italian Myeloma Network, Rionero In Vulture, Italy
[9] GIMEMA, Italian Myeloma Network, Cremona, Italy
[10] GIMEMA, Italian Myeloma Network, Genoa, Italy
[11] GIMEMA, Italian Myeloma Network, Piacenza, Italy
[12] GIMEMA, Italian Myeloma Network, Varese, Italy
[13] GIMEMA, Italian Myeloma Network, Turin, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P239
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [21] Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma
    Cavo, Michele
    Galli, Monica
    Pantani, Lucia
    Di Raimondo, Francesco
    Crippa, Claudia
    Offidani, Massimo
    Zamagni, Elena
    Montefusco, Vittorio
    Narni, Franco
    Pezzi, Annalisa
    Spadano, Antonio
    Pescosta, Norbert
    Tacchetti, Paola
    Baldini, Luca
    Ledda, Antonio
    Cellini, Claudia
    Caravita, Tommaso
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Boccadoro, Mario
    [J]. BLOOD, 2012, 120 (21)
  • [22] Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma
    Cavo, Michele
    Tacchetti, Paola
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Pantani, Lucia
    Ceccolini, Michela
    Galli, Monica
    Di Raimondo, Francesco
    Crippa, Claudia
    Zamagni, Elena
    Tosi, Patrizia
    Nami, Franco
    Bringhen, Sara
    Montefusco, Vittorio
    Offidani, Massimo
    Buttignol, Silvia
    Levi, Anna
    Gorgone, Ausilia
    Brioli, Annamaria
    Pallotti, Maria Caterina
    Spadano, Tonino
    Pescosta, Norbert
    Baldini, Luca
    Ledda, Antonio
    Caravita, Tommaso
    Falcone, Antonietta
    Zaccaria, Alfonso
    Perrone, Giulia
    Petrucci, Alessandro
    Palumbo, Antonio
    Boccadoro, Mario
    Baccarani, Michele
    [J]. BLOOD, 2008, 112 (11) : 65 - 65
  • [23] Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM).
    Weber, D
    Albitar, M
    Delasalle, K
    Dey, A
    Rankin, K
    Gavino, M
    Walker, P
    Alexanian, R
    [J]. BLOOD, 2002, 100 (11) : 808A - 809A
  • [24] Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
    Cavo, Michele
    Pantani, Lucia
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Galli, Monica
    Di Raimondo, Francesco
    Rossi, Giuseppe
    Palumbo, Antonio
    Tacchetti, Paola
    Offidani, Massimo
    Montefusco, Vittorio
    Narni, Franco
    Spadano, Tonino
    Cellini, Claudia
    Pescosta, Norbert
    Baldini, Luca
    Ledda, Antonio
    Di Toritto, Tommaso Caravita
    Pezzi, Annalisa
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Gherlinzoni, Filippo
    Petti, Maria Concetta
    Derudas, Daniele
    Ballanti, Stelvio
    De Stefano, Valerio
    Baccarani, Michele
    [J]. BLOOD, 2011, 118 (21) : 816 - 816
  • [25] Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency
    Tosi, Patrizia
    Zamagni, Elena
    Tacchetti, Paola
    Ceccolini, Michela
    Perrone, Giulia
    Brioli, Annamaria
    Pallotti, Maria Caterina
    Pantani, Lucia
    Petrucci, Alessandro
    Baccarani, Michele
    Cavo, Michele
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1115 - 1121
  • [26] VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.
    Alexaman, R
    Wang, LM
    Weber, DM
    Delasalle, KB
    [J]. BLOOD, 2004, 104 (11) : 64A - 64A
  • [27] Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis
    Terragna, Carolina
    Zamagni, Elena
    Petrucci, Maria Teresa
    Durante, Sandra
    Patriarca, Francesca
    Narni, Franco
    Crippa, Claudia
    Gorgone, Ausilia
    Caravita, Tommaso
    Perrone, Giulia
    Nozzoli, Chiara
    Masini, Luciano
    Callea, Vincenzo
    Attolico, Immacolata
    Cellini, Claudia
    Bringhen, Sara
    Ledda, Antonio
    Montefusco, Vittorio
    Martello, Marina
    Martinelli, Giovanni
    Baccarani, Michele
    Cavo, Michele
    [J]. BLOOD, 2010, 116 (21) : 376 - 376
  • [28] Prediction of response to primary therapy with thalidomide-dexamethasone(Thal-DEX) for newly diagnosed multiple myeloma by gene expression profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A. M.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 177 - 177
  • [29] Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by Gene Expression Profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M. C.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 138 - 138
  • [30] Thalidomide-Dexamethasone vs Interferon-α-Dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma (MM):: Final analysis of a prospective, randomized study.
    Polloni, Claudia
    Corvatta, Laura
    Piersantelli, Maria-Novella
    Galieni, Piero
    Visani, Giuseppe
    Alesiani, Francesco
    Catarini, Massimo
    Brunori, Marino
    Burattini, Maurizio
    Centurioni, Riccardo
    Ferranti, Mario
    Giuliodori, Luciano
    Candela, Marco
    Mele, Anna
    Marconi, Monica
    Leoni, Pietro
    [J]. BLOOD, 2007, 110 (11) : 164A - 164A
12345